 1. Signed informed consent 2. Male or female aged 18 years or above 3. Histological diagnosis of MTC 4. Patients with symptomatic and aggressive sporadic MTC, who have unresectable, locally advancedmetastatic disease. The factors considered by the investigator to determine a patients disease to be symptomatic and aggressive will be recorded in the CRF. 5. Measurable disease: 